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ABSTRACT
Background
The rectum is particularly vulnerable to HIV transmission having only a single protective layer of
columnar epithelium overlying tissue rich in activated lymphoid cells; thus, unprotected anal
intercourse in both women and men carries a higher risk of infection than other sexual routes. In the
absence of effective prophylactic vaccines, increasing attention is being given to the use of
microbicides and preventative antiretroviral (ARV) drugs. To prevent mucosal transmission of HIV, a
microbicide/ARV shouldideallyactlocallyatand nearthe virusportal of entry.Aspart of anintegrated
rectal microbicide development programme, we have evaluated rectal application of the nucleotide
reverse transcriptase (RT) inhibitor tenofovir (PMPA, 9-[(R)-2-(phosphonomethoxy) propyl] adenine
monohydrate), a drug licensed for therapeutic use, for protective efficacy against rectal challenge
with simian immunodeficiency virus (SIV) in a well-established and standardised macaque model.
Methods and Findings
A total of 20 purpose-bred Indian rhesus macaques were used to evaluate the protective efficacy of
topical tenofovir. Nine animals received 1% tenofovir gel per rectum up to 2 h prior to virus challenge,
four macaques received placebo gel, and four macaques remained untreated. In addition, three
macaques were given tenofovir gel 2 h after virus challenge. Following intrarectal instillation of 20
median rectal infectious doses (MID50) of a noncloned, virulent stock of SIVmac251/32H, all animals were
analysed for virus infection, by virus isolation from peripheral blood mononuclear cells (PBMC),
quantitative proviral DNA load in PBMC, plasma viral RNA (vRNA) load by sensitive quantitative
competitive (qc) RT-PCR, and presence of SIV-specific serum antibodies by ELISA. We report here a
significant protective effect (p¼ 0.003; Fisher exact probability test) wherein eight of nine macaques
giventenofovirperrectumupto2hpriortoviruschallengewereprotectedfrominfection(n¼6)orhad
modified virus outcomes (n ¼ 2), while all untreated macaques and three of four macaques given
placebo gel were infected, as were two of three animals receiving tenofovir gel after challenge.
Moreover, analysis of lymphoid tissues post mortem failed to reveal sequestration of SIV in the
protectedanimals.Wefoundastrongpositiveassociationbetweentheconcentrationoftenofovirinthe
plasma 15 min after rectal application of gel and the degree of protection in the six animals challenged
with virus at this time point. Moreover, colorectal explants from non-SIV challenged tenofovir-treated
macaqueswereresistanttoinfectionexvivo,whereasnoinhibitionwasseeninexplantsfromthesmall
intestine. Tissue-specific inhibition of infection was associated with the intracellular detection of
tenofovir. Intriguingly, in the absence of seroconversion, Gag-specific gamma interferon (IFN-c)-
secreting T cellsweredetectedinthe blood offour of sevenprotectedanimalstested, withfrequencies
ranging from 144 spot forming cells (SFC)/10
6 PBMC to 261 spot forming cells (SFC)/10
6 PBMC.
Conclusions
These results indicate that colorectal pretreatment with ARV drugs, such as tenofovir, has
potential as a clinically relevant strategy for the prevention of HIV transmission. We conclude that
plasma tenofovir concentration measured 15 min after rectal administration may serve as a
surrogate indicator of protective efficacy. This may prove to be useful in the design of clinical
studies. Furthermore, in vitro intestinal explants served as a model for drug distribution in vivo and
susceptibility to virus infection. The finding of T cell priming following exposure to virus in the
absence of overt infection is provocative. Further studies would reveal if a combined modality
microbicide and vaccination strategy is feasible by determining the full extent of local immune
responses induced and their protective potential.
The Editors’ Summary of this article follows the references.
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The development of an effective vaccine against HIV is still
thought to be a long-term endeavour; meanwhile the HIV
pandemic continues relentlessly, fuelled primarily by sexual
transmission. The relative ease by which HIV is transmitted
rectally [1–4] makes this a particularly important, although
relatively neglected, route to target with prevention strat-
egies. Unlike the vagina, the rectal canal has only a single
l a y e ro fc o l u m n a re p i t h e l i u mo v e r l y i n gt i s s u er i c hi n
activated lymphoid cells [5,6] and therefore for reasons of
both anatomy and immunological status presents a particular
challenge for preventative modalities. It is difﬁcult to
estimate the prevalence of anal intercourse (AI) in the
heterosexual population, but recent studies have indicated
that it may be far more common than had been thought. In a
population-based study of 2,547 Northern Californian wom-
en aged 18–29 y, AI was reported in 21.7% of sexually active
individuals [7]. Higher rates of AI have been described in
women at particular risk of HIV infection through drug use,
forced intercourse, and prostitution [8–11]. Data from Africa
are very limited, but levels in excess of 40% incidence have
been described in commercial sex workers in South Africa
[12,13]. These ﬁgures alone demonstrate the need for the
development of rectal microbicides, a focus catalyzed by the
more visible need of the population of men who have sex with
men, which still accounts for the majority of new infections in
North America, South America, and Europe. Moreover, many
of these men who have sex with men are having unprotected
AI irrespective of their HIV status [14]. In the absence of
vaccines, increasing effort is being applied to the parallel
approach of preventative microbicides/pre-exposure use of
antiretrovirals (ARVs). To date preclinical studies of tenofo-
vir in the macaque rectal challenge model using either simian
immunodeﬁciency virus (SIV) or recombinant chimeric
simian HIV (SHIV) have focussed on the use of the orally
bio-available prodrug tenofovir disoproxil fumarate (TDF)
[15,16]. Although partial protection was observed against
multiple low dose mucosal virus challenge, it appeared that
the dose of available drug may have been suboptimal. We
have taken a different approach, reasoning that the optimal
route to protect cells of the rectum and possibly beyond may
be through local application of tenofovir given, in effect, as a
rectal microbicide. As well as testing this hypothesis, we
sought to determine if protective efﬁcacy correlated with
drug uptake and whether exposure to virus in the absence of
overt infection stimulated virus-speciﬁc T cell responses.
Methods
Macaques, Tenofovir Gel, and Virus
A well-established macaque rectal challenge model using
uncloned SIVmac251/32H; a virus that results in high cell-
associated and plasma viral RNA (vRNA) loads shortly after a
single application to naı ¨ve macaques [17–20] was used for this
study. Purpose-bred male rhesus macaques (Macaca mulatta)o f
Indian origin aged 4–6 y were obtained from a UK breeding
colony. All animals were housed according to the Code of
Practice of the UK Home Ofﬁce (1989) and were sedated with
ketamine hydrochloride prior to inoculation with virus and/
or venepuncture. Animals were killed humanely by an
overdose of anaesthetic. All procedures involving animals
were approved by the Ethical Review Committee of the
Centre for Emergency Preparedness and Response, Salisbury,
UK. None of the animals had been used previously for
experimental procedures and all animals were shown to be
SIV negative (by virus isolation [VI], PCR, and serology)
before entering the experiment. Tenofovir gel (1%) or
control placebo gel, a proprietary formulation containing
puriﬁed water with edetate disodium, citric acid, glycerin,
methylparaben, propylparaben, and hydroxyethylcellulose
(pH 4.5) supplied by Gilead Sciences was transferred to 5-
ml syringes and administered in 3-ml volumes via a 10 FG soft
catheter introduced 8 cm into the rectum. The process was
atraumatic with no obvious leakage. Assignment of macaques
to different treatment groups is shown in Table 1.
All macaques were challenged with 20 median rectal
infectious doses MID50 of SIVmac 251/32H 11/88 stock
equivalent to 18,974 50% tissue culture doses (TCID50)a s
determined by previous titration [18]. Virus inoculum was
diluted aseptically shortly before challenge and administered
in 3-ml volumes with a 6 FG soft catheter 8 cm into the
rectum. At 1, 2, 6, 12, 16, and 20 wk postchallenge macaques
were bled to provide 15 ml of heparinised blood for VI and
proviral DNA assay, 2 ml of EDTA blood for plasma vRNA
load determination, and 2 ml of clotted blood for serum
antibody analysis. Animals were observed for adverse effects
immediately after injection of test substance, followed by
daily observation for the duration of study. At each time of
sedation the following clinical data were taken for each
animal: body weight, temperature, axillary and inguinal
lymph node scores, and haemoglobin concentration. Nec-
ropsies were performed on all the animals from which SIV
had not been recovered and on two SIV-infected animals. At
necropsy, the animals were assessed for gross pathology and
the following specimens collected for analysis: heparinised
blood, spleen, inguinal, mesenteric, and iliac lymph nodes, 20-
cm sections of ileum/jejunum, and colorectum tissue. The gut
tissues were washed to remove faecal material and each
sample placed into 20 ml of RPMI supplemented with L-
glutamine (2 mM), penicillin (50 U/ml), streptomycin (50 lg/
ml), and gentamicin (80 lg/ml) before rapid transport to the
laboratory (3–4 h) on water ice for explant culture. All other
tissues, as well as small samples of the gut tissues, were frozen
at  70 8C for later analysis by PCR.
Two other SIV-naı ¨ve rhesus macaques were used to obtain
gut tissues for explant studies of tenofovir antiviral activity in
vitro (see below). A further four SIV-naı ¨ve macaques were
Table 1. Assignment of Macaques to Experimental Groups
Study Group Animal
Number
Procedure
Evaluation of
protective efficacy
of rectal tenofovir
A D3, D30, D37,
D39, D43, D79
Tenofovir 15 min before virus
B C57, D9, D26, D68 Placebo 15 min before virus
C D77, D83, E73, E81 No treatment before virus
D D14, D69, D56 Tenofovir 2 h before virus
E D15, D18, D29 Tenofovir 2 h after challenge
Explant studies F M3, M6 No treatment before necropsy
G M1, M5, M32, M38 Tenofovir 3 h before necropsy
doi:10.1371/journal.pmed.0050157.t001
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necropsy, and gut tissues used for ex vivo analysis of
intracellular drug concentration and viral inhibitory activity
(Table 1).
Virus Isolation
At each time point of sampling, 2 3 10
6 peripheral blood
mononuclear cells (PBMC) were cocultured with C8166 cells
essentially as described previously [21]. Cultures were
examined at the time of feeding every 3–4 d for cytopathic
effect (cpe). Cultures where cpe was not seen were kept for at
least 28 d. Virus growth was conﬁrmed by immunoﬂuorescent
staining of acetone-methanol ﬁxed cells for the detection of
SIV antigens using a polyclonal antiserum from an SIV
infected macaque. A similar procedure was used for back
titration of the challenge stock virus, where 10-fold dilutions
were added to four replicate ﬂasks of C8166 cells for each
dilution tested.
Plasma vRNA
Plasma vRNA concentrations were determined by quanti-
tative competitive (qc) real time reverse transcriptase (RT)-
PCR with a cut-off sensitivity of 40 RNA equivalents/ml [22].
Cell Associated Proviral DNA
Levels of proviral SIV gag DNA were determined using a
highly sensitive PCR assay. Genomic DNA was extracted from
whole blood or lymphoid samples by proteinase K digestion
and phenol/chloroform using standard protocols, and the
amount included in each PCR determined retrospectively by
microﬂuorometry using a total DNA quantiﬁcation kit on the
basis of calf-thymus DNA standards (Sigma). One microlitre
aliquots of DNA extract were assayed, in triplicate, using a
Taqman Universal PCR Master mix (Applied Biosystems) with
primers and probe located in conserved regions of gag. Ten-
fold serial dilutions of a p2-LTR plasmid [23], which
encompasses the target gag sequences and diluted in 60 lg/
ml herring sperm DNA, were included in each run as controls.
Primer sequences were 59-AGTGCCAACAGGCTCAGAAAA-
39 (forward, 1253–1273) and 59- TGCGTGAATGCACCA-
GATG-39 (reverse, 1304–1322) numbering based on SIVmac239,
at an optimal concentration of 900 nM for each primer.
Taqman hydrolysis probe sequence 59-(69-FAM-
TTAAAAAGCCTTTATAATACTGTCTGCG-BHQ1)-39 (for-
ward, 1275–1301) was used at a concentration of 225 nM.
Ampliﬁcations were performed on an Mx3000P genetic
analyser (Stratagene) with a thermoproﬁle of initial HotStart
of 95 8C/10 min, followed by 95 8C/30 s, and 60 8C, 1 min/45
cycles. Quantitative SIV DNA levels were calculated using the
Mx3000P software, expressed as copies of SIV DNA per 10
5
PBMC/mononuclear cells (MNC). The absolute detection limit
of the assay, as determined by Poisson statistics, was a single
SIV DNA copy. Similar data were generated on DNA extracted
from low-copy number SIV-infected cell preparations where
the actual copy number per PCR reaction was determined to
be 1.48 copies of SIV gag DNA. Each assay was controlled
internally with a spiked DNA preparation and validated by
detection of ,three copies of SIV DNA.
Tenofovir Quantification
Plasma samples were assayed for tenofovir concentration by
the Clinical Pharmacology and Analytical Chemistry Core of
the University of North Carolina Center for AIDS Research.
Drug concentrations in plasma were determined by a
validated high pressure, liquid chromatography (HPLC)
method with ultraviolet detection [24]. This method utilized
a dynamic range of 10–10,000 ng/ml, with intra- and interday
variability of ,10% across this range. Total tenofovir
concentrations were assayed in tissues using a fully validated
HPLC method with mass spectrometry detection (S. Choi, et
al., unpublished data). Brieﬂy, internal standard (tolbutamide)
was added to tissue prior to complete homogenization using a
Fast prep-24 Homogenizer and Lysing Matrix A (MP
Biomedicals). Samples were subjected to solid phase extrac-
tion on a Varian Bond Elut-C18 column. Chromatographic
separation of TNF and the internal standard (tolbutamide)
was achieved with a Varian Polaris 3C18-A, 150 mm 3 2 mm,
reversed phase analytical column, using a gradient method of
0.1% formic acid in water and 0.1% formic acid in
acetonitrile. Detection of TNF and tolbutamide was achieved
by electrospray ionization MS in the positive mode using
288.05 and 271.00 m/z, respectively. Linear tenofovir calibra-
tion curves were obtained between 1.0 and 1,000.0 ng/ml, with
a correlation coefﬁcient (r
2) greater than 0.999. Intra- and
interday accuracy for tenofovir ranged from 89.7% and
109.4% and from 97.3% and 104.9%, and precision ranged
from 1.3% and 10.9% and 2.6% and 9.0%, respectively. Assays
were performed with and without incubating tissue with
phosphatase, to enable comparison between total parent
tenofovir concentrations, and indirect measures of the
combination of mono- and diphosphate (active compound)
concentrations. Both approaches were validated according to
Food and Drug Administration (FDA) standards (http://www.
fda.gov/cder/guidance/) with respect to calibration curve
performance, recovery, intra- and interday accuracy, and
precision of the method, stability of the analytes at various test
conditions (determined by TNF and TNF-DP QC perform-
ance), evaluation of speciﬁcity and matrix effect, and
comparisons of differences between fresh and frozen tissue.
Gamma Interferon Elispot and Antibody Assay
Freshly isolated tissue-derived MNC [25] and cryo-pre-
served PBMC were used in the analysis of T cell function. The
frequency of SIV speciﬁc T cells secreting gamma interferon
(IFN-c) was determined by ELISpot essentially as described
previously [26] but using pools of SIVmac251/32H 15 mer
peptides, made on the basis of epitope prediction: Gag pool
(EVA7066.1–16); Nef pool 1 (EVA7067.1–16); Nef pool 2
(EVA7067.17–29); Tat pool (EVA7069.1–10); Rev pool
(EVA7068.1–8). Peptides were made as part of Programme
EVA and supplied from the Centralised Facility for AIDS
Reagents, National Institute of Biological Standards &
Control, UK (www.nibsc.ac.uk/catolog/aids-reagent). All assays
were carried out in triplicate, using 2 3 10
5 cells/well and a
ﬁnal peptide concentration of 10 lg/ml for each component
of the pool. The frequency of spot forming units (SFUs) was
determined with a reader (AID). Background-subtracted
frequencies of SIV-speciﬁc IFN-c–secreting T cells above 50
SFU)/10
6 cells and at least twice the standard deviation of the
control were considered as positive.
In Vitro Assay of Infectivity Inhibition in Indicator Cells and
Explant Cultures
Full-length, replication and infection competent proviral
HIV-1 clones pYU2 [27,28] and pNL4–3 [29] were provided by
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(http://www.aidsreagent.org/).
TZM-bl cells, a CXCR4-positive HeLa cell clone engineered
to express CD4 and CCR5 and to contain integrated reporter
genes for ﬁreﬂy luciferase and Escherichia coli b-galactosidase
under the control of an HIV long terminal repeat sequence,
were obtained from the NIH AIDS Research and Reference
Reagent Program and were grown at 37 8C in Dulbecco’s
Minimal Essential Medium containing 10% foetal calf serum,
2 mM L-glutamine, and antibiotics (100 U of penicillin/ml,
100 lg of streptomycin/ml). For quantiﬁcation of virus
infectivity cells were seeded at 3 3 10
3 cells/well 24 h before
addition of virus. After incubation with virus for 2 d, the cells
were washed with PBS and treated with 100 ll of luciferase
cell culture lysis reagent. As previously described [30], 50 llo f
each lysate was transferred to a white, opaque assay plate for
luciferase quantiﬁcation in a Synergy HT Multi-Detection
Microplate Reader (BioTek Instruments) using 50 llo f
luciferase assay reagent (Promega). The extent of luciferase
expression was recorded in relative light units (r.l.u.). Virus
infectivity inhibition assays were performed using a stand-
ardized amount of virus culture supernatants normalized for
infectivity. Cells were incubated with serial dilutions of drugs
for 1 h at 37 8C, and then virus was added to cells and left for
48 h. Fifty percent inhibitory concentrations (IC50) were
calculated from the sigmoidal dose response curves.
Colorectum and ileum–jejenum explants were prepared
and cultivated at an air-media interface as described
previously for human tissue [31]. Brieﬂy, after two washes
and removal of the muscle from the resected tissue, 2–3 mm
3
explants were cut. Explants from nontreated animals were
incubated with or without PMPA at 100 lg/ml for 1 h and
then incubated with SIVmac251/32H for 2 h without removal of
the drug. Explants from tenofovir-treated animals were
incubated directly with virus. After four washes in PBS, the
explants were cultivated on gelfoam (Pharmacia & Upjohn)
for 15 d with Dulbecco’s Minimal Essential Medium (Sigma)
containing 10% foetal calf serum, 2 mM L-glutamine, 100 U/
ml penicillin, 100 lg/ml streptomycin, and 80 lg/ml gentami-
cin. Assays were performed with four replicate wells per
sample each well containing three explants. Supernatants
were harvested at 3, 7, 11, and 15 d and Gag p27
concentrations were measured by ELISA (p27 antigen ELISA,
Zeptometrix Corporation) following the manufacturer’s
instructions.
Statistical Analysis
The signiﬁcance of the protection data was determined
using the two-tailed Fisher exact probability test by manual
calculation. Drug activity titration curves were compared by
cross-sectional time series analysis using Stata v10 (Stata
Corp). p-values of ,0.05 were considered to be signiﬁcant.
Results
Comparison of Tenofovir-Mediated Inhibition of HIV-1 and
SIV Replication In Vitro
Having shown that tenofovir had no evidence of toxicity on
TZM-bl cells, as assessed by MTT viability assay at the highest
dose tested (unpublished data), we initially compared the
activity of tenofovir, formulated as a solution from PMPA
powder or formulated as a gel, as supplied by Gilead Sciences,
against a panel of HIV-1 isolates with alternative secondary
receptor usage (CXCR4-using RF, IIIB, and NL4.3; CCR5-
using BaL, YU.2, and R8BaL) and against SIVmac251/32H; the
latter being used for the macaque challenge experiments.
There was no evidence of any difference in the mean average
level of inhibition of SIVmac251/32H replication with either
formulation at any dose (p¼0.89). This result was determined
allowing for the inherent correlation across doses within the
same intervention group using cross-sectional time series
analysis. Furthermore, tenofovir IC50 values for SIVmac251/32H
were of the same order of magnitude as those measured
against both R5 and X4 restricted isolates of HIV (Figure 1).
Dosing and Outcome of Virus Challenge
We used a 1% tenofovir gel formulation made and supplied
by Gilead Sciences as part of a programme on the develop-
ment of a vaginal microbicide. Although this formulation had
not been optimised for rectal use, we considered that it would
provide a suitable starting point for preclinical evaluation.
No adverse effects were seen following rectal gel admin-
istration. Virological analysis over a 20-wk period after rectal
challenge with 20 MID50 showed that four of six animals in
group A (tenofovir 15 min before challenge) and two of three
animals in group D (tenofovir 2 h before challenge) were
protected from systemic infection on the basis of failure to (a)
recover virus from PBMC, (b) to detect proviral DNA in
PBMC, (c) to detect vRNA in plasma, and (d) to detect SIV-
speciﬁc antibodies in serum. All the naı ¨ve/not-dosed animals
and three of four animals receiving placebo gel were infected
and had high levels of circulating vRNA, and proviral DNA
and virus was recoverable from the PBMC at all times of
testing (Figure 2). This protective effect just reached
statistical signiﬁcance at p ¼ 0.05 (Table 2). Furthermore, in
comparison with the controls, two of three animals given
tenofovir rectally prechallenge that became infected had
modiﬁed virological outcomes. Virus was recovered from the
PBMCs of animal D43 only at weeks two and six correspond-
ing to the only times that vRNA was detected in plasma.
Interestingly, the proviral DNA load remained below 50
copies/10
5 PBMC and by week 20, the last point of sampling,
had declined to just above the limit of detection. In animal
D56 the earliest time of virus detection by any of the methods
used was 12 wk after challenge; a delay not seen in other
animals in this study or in control animals rectally infected
with the same virus stock in previous studies. Taken together,
these data showed that tenofovir gel administered at least up
to 2 h prior to virus challenge had a signiﬁcant protective
effect (p ¼ 0.003) (Table 3). Inclusion of another 17 naı ¨ve
controls that had been challenged intrarectally with the same
virus challenge stock [17–20] revealed a highly signiﬁcant
level of protection from detectable virus infection (p , 0.001)
(Table 4). One of three animals given similar intrarectal
dosing 2 h after virus challenge (group E) was protected from
infection. Back titration of the virus challenge stock in C8166
cells conﬁrmed infectivity titre had been maintained upon
storage.
Of the eight animals that remained VI/PCR negative, seven
were clinically normal throughout the study, and one, D68,
which had received placebo gel, whilst clinically normal at
necropsy had enlarged axillary and inguinal nodes at week 12.
In contrast, all of the animals in which virus was recovered at
high frequency had some clinical signs and/or necropsy
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axillary and inguinal lymph nodes, and splenomegaly. One
animal, D83, had evidence of progression to AIDS including
loss of weight, tenting of skin, lung abnormalities including,
grey discolouration, numerous petechial haemorrhages on
the surface, and adhesions to the thoracic wall. Animal D43,
which had been given tenofovir 15 min prior to virus
challenge and showed only a weak and transient viraemia,
remained clinically normal throughout the study.
To determine if virus was sequestered in tissue associated
with the virus challenge, quantitative proviral PCR was used
to examine MNC isolated from rectum and ileum, as well as
iliac, inguinal, and mesenteric lymph nodes. In the apparently
protected animals, there was no evidence of infection
whereas in animal E81, a naı ¨ve challenged control, proviral
loads of 26, 5, 130, 2,100, and 105 proviral DNA copies/10
5
MNC equivalents were detected in each tissue respectively.
T Cell Responses in Protected Animals
To determine if mucosal exposure to virus in the absence
of overt infection had stimulated T cell immunity, SIV-
speciﬁc IFN-c ELISpot analysis was performed on PBMC
from protected animals and one infected animal (E81) taken
20 wk after challenge. Four of seven protected animals had
IFN-c-secreting Gag-speciﬁc T cells at frequencies ranging
from 144 to 261 SFU/10
6 cells, whereas the infected animal
E81 had both Gag and Tat-speciﬁc circulating T cells (Figure
3A). In contrast, no signiﬁcant reactivity was seen in 12 naı ¨ve
macaques tested (,40 SFU/10
6 cells). The ﬁnding of T cell
responses in the virus exposed macaques was found to be
statistically signiﬁcant; p ¼ 0.009 (Fisher exact test). Interest-
ingly, the presence of Gag-speciﬁc IFN-c secreting T cells in
animal D68 (pre-exposed to placebo gel) conﬁrmed that
challenge virus gained access to antigen presenting cells.
Interpretation of T cell reactivity in MNC from colorectal
tissue was precluded by a very high spontaneous back-
ground; however, MNC from the small intestine of three of
four protected animals contained SIV-speciﬁc IFN-c-secret-
ing T cells with broader antigen speciﬁcity (including
speciﬁcity for nonstructural virus-encoded antigens) and in
two of these cases no responses in PBMC (Figure 3B). Thus
the local mucosal immune system may have been primed by
SIV antigens produced de novo during drug-modulated
abortive or limited infection. Despite evidence of T cell
priming, none of the protected animals had detectable SIV-
speciﬁc serum antibodies (Figure 3C).
Plasma Tenofovir Concentration and Protection Status
Analysis of plasma tenofovir concentration at the time of
virus challenge, 15 min after gel administration, revealed a
Figure 1. Solution and Gel Formulated Tenofovir Inhibited SIVmac251/32H Infectivity In Vitro at Similar Doses and in the Same Range as for Representative
HIV-1 Isolates
Infection of TZM-bl indicator cells in the presence and absence of tenofovir was compared by luminescence analysis of cell lysates and the results
expressed as percent inhibition. The graph shows the full titration of drug formulations on infection with SIVmac251/32H; the virus stock used in
subsequent challenge experiments in vivo. Each point represents the mean of three independent experiments performed in triplicate þ/  standard
deviation. The results for a panel of HIV-1 strains in comparison to SIVmac251/32H are shown as IC50 values in the inset.
doi:10.1371/journal.pmed.0050157.g001
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concentration of plasma tenofovir associated with protection
as deﬁned by failure to isolate and/or detect virus in PBMC
and plasma and lack of seroconversion, was 119.9 ng/ml
(Table 5). Taking into account estimated plasma volume,
protection was associated with as little as 0.11% of the total
tenofovir applied. Moreover, an effect upon plasma viraemia
was observed with as little as 0.06% of applied tenofovir
detected in plasma at 15 min. In animals given tenofovir 2 h
prior virus challenge plasma tenofovir, at the time of
challenge ranged between below the 10 ng/ml limit of
detection to 23.3 ng/ml. These results suggested therefore
that drug concentration peaked rapidly after rectal dosing.
Ex Vivo Modelling of Tenofovir Activity
T of u r t h e ra d d r e s st h ep o s s i b l em e c h a n i s mo ft h e
protection observed we utilised our recently described in
vitro colorectal explant model [31] and adapted it to macaque
tissue. Using tissues from another group of SIV-naı ¨ve
macaques (group F), ﬁrst, we demonstrated that SIVmac251/
32H replicated in this system and that replication was sensitive
to addition of tenofovir in vitro (Figure 4A). We also found
similar replication in ileum–jejunum explants (unpublished
data). Interestingly, replication in macaque explants peaked
earlier (day seven) and at a lower level than that seen for HIV
in human explants as determined by Gag p27/24 production
(C. Herrera, unpublished data and [31]), regardless of virus
dose. Next, we investigated the replication kinetics in
intestinal tissue explants taken from another four SIV naı ¨ve
macaques that were given tenofovir gel in vivo 3 h prior to
necropsy (group G). In colorectal explants from three of four
animals, complete or nearly complete inhibition of virus
replication was seen and in the other animal a high level of
variability between replicate samples resulted in lower mean
Figure 2. Rectal Administration of Tenofovir Gel Protected a High Proportion of Macaques against Subsequent Acquisition of SIV by Rectal Transmission
The results of VI from PBMC are shown asþor for each animal. The temporal profiles of plasma vRNA concentration (red dot) and frequency of PMBC-
associated proviral DNA (blue triangle) are shown for each animal in the study.
doi:10.1371/journal.pmed.0050157.g002
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Blockade of SIV Rectal Infectioninhibition (Figure 4B). In contrast, inhibition of virus
replication was not seen in explants from the small intestine
(unpublished data) suggesting that tenofovir was, at least in
part, acting on cells at the virus portal of entry. Analysis of
intestinal tissue samples collected at necropsy showed that all
tenofovir-dosed animals had measurable concentrations of
drug in lysates of colorectal tissue at concentrations between
20.8 and 54.2 lg/g protein but no drug was detected in lysates
of homogenates from the small intestine (Table 6). Tissues
from untreated animals (group F) acted as negative controls.
To indirectly estimate the amount of intracellular phos-
phorylated tenofovir in tissues, samples were analysed with
(to measure the combination of tenofovir þ tenofovir
monophosphate þ tenofovir diphosphate) and without (to
measure tenofovir only) phosphatase hydrolysis. Subtracting
the concentration of tenofovir obtained from tissue samples
without phosphatase, from the concentration of tenofovir
obtained from tissue samples with phosphatase, demonstra-
ted that between 46%–75% of total tenofovir in tissues was
present as the intracellular mono- and diphosphate forms.
On the basis of intracellular data describing tenofovir
monophosphate:diphosphate ratios [32–34], it was estimated
that approximately 30%–60% of total tenofovir in tissues was
present as the intracellular diphosphate form.
Discussion
Summary of Results
The preclinical study reported here using the SIV-macaque
challenge model, showing a statistically signiﬁcant protective
effect, strongly supports the notion that local application of
an ARV agent can efﬁciently protect against subsequent
intrarectal challenge with virus. In addition, the study
revealed a potential metric of protective efﬁcacy wherein,
above a critical threshold, the concentration of tenofovir
detectable in the plasma 15 min after rectal application was
positively associated with protection. Topical use of tenofovir
prior to virus exposure also facilitated the priming of SIV-
speciﬁc T cell responses in a proportion of macaques,
opening up the possibility that this type of prophylaxis may
be able to prime and/or boost immune responses elicited with
experimental vaccines.
Protection from Infection
It has become increasingly evident that current experi-
mental approaches to the development of an HIV vaccine,
largely based upon the generation of T cell immunity, are, at
best, likely only to reduce the level of viraemia following
exposure to virus. Although this may have partial beneﬁt, in
the longer term, as shown in the SIV model, virus frequently
escapes from immune control following the selection of
variants mutated in T cell epitopes [35,36]. The development
of mucosal targeted vaccines, that may be able to completely
prevent infection, is a major roadblock to progress and has
refocused the ﬁeld on prevention of infection at the viral
portal of entry. The concept of using ARVs topically to
prevent infection with HIV is gaining momentum and several
clinical trials are currently in progress [37]. The ﬁndings
reported here showing protection from overt infection in six
of nine macaques against rectal transmission of SIV after
topical application of tenofovir gel, suggest that this
approach has high potential for clinical translation. Interest-
ingly, even in two of three unprotected animals a delay in
appearance of viraemia (D56) or a low, transient viraemia
(D43) was seen. Although it is not possible to rule out that
these effects were due to natural animal-to-animal variability,
the VI proﬁles were highly atypical compared to those
observed in our previous studies with this stock of virus
[17,18]. We suggest that there may have been low level seeding
of virus into a sparse population of cells containing
suboptimal concentrations of drug and that the majority of
target cells were blocked by tenofovir providing only limited
potential for local replication of virus.
The long intracellular half-life of tenofovir diphosphate,
the pharmacologically active metabolite of tenofovir [32,33],
potentially makes tenofovir an ideal compound for topical
use. Indirect analysis to measure total intracellular phos-
phorylated tenofovir (mono- and diphosphate combined)
concentration in rectal tissue, taken from animals dosed in
vivo, indicated that up to approximately 60% of the drug had
been converted to the active form. It is known that the
metabolism of tenofovir varies in different cell types, at least
Table 2. Contingency Table for Dosing and Outcome of Virus
Challenge: Analysis for ‘‘Complete’’ Protection (i.e., No Virus
Detection) Associated with Tenofovir Gel Administered Intra-
rectally Prior to Virus Challenge; p ¼ 0.05
Dosing Infected Not Infected
Tenofovir 3 6
No tenofovir 7 1
doi:10.1371/journal.pmed.0050157.t002
Table 3. Contingency Table for Dosing and Outcome of Virus
Challenge: Analysis for Modified Outcome (i.e., ‘‘Complete’’
Protection or Reduced Frequency of Virus Detection) Associated
with Tenofovir Gel Administered Intrarectally Prior to Virus
Challenge; p ¼ 0.003
Dosing Infected (High Frequency
Detection . 80%)
Not Infected or
Modified Infection
Tenofovir 1 8
No tenofovir 7 1
doi:10.1371/journal.pmed.0050157.t003
Table 4. Contingency Table for Dosing and Outcome of Virus
Challenge: Analysis for ‘‘Complete’’ Protection, Including His-
torical Controls Challenged with the Same Virus Stock Intra-
rectally, Associated with Tenofovir Gel Administered Intrarectally
Prior to Virus Challenge; p , 0.001
Dosing Infected Not Infected
Tenofovir 3 6
No tenofovir 24 1
doi:10.1371/journal.pmed.0050157.t004
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Blockade of SIV Rectal Infectionin vitro [33,34]. Of particular relevance to the present study,
it has been reported that in dendritic and Langerhans cells
the mono- to diphosphate ratio is approximately 1:3 depend-
ent upon time of sampling [34]. It was encouraging that two
of three animals given tenofovir 2 h prior to virus challenge
were protected against overt infection. Further experiments
are now required to fully determine the longevity of
protection and its relationship of tenofovir metabolism in
rectal tissue.
Another critical consideration is whether protective
efﬁcacy can be increased to 100%. Of particular interest in
the present study was the observation of a positive association
between the concentration of tenofovir measured in the
circulation 15 min after topical application and the outcome
Figure 3. SIV-Specific IFN-c Secreting T Cells Were Detected in SIV-Challenged Macaques in the Absence of Serum Antibody Responses and Evidence of
Overt Infection
(A) IFN-c secreting T cell frequencies in PBMC from protected animals (D68–D14) compared to those in an SIV-infected animal (E81) measured 20 wk
after virus exposure measured by ex vivo ELISpot. The mean frequencies of three replicate determinations plus one standard deviation are shown for
each peptide pool used.
(B) SIV-specific IFN-c secreting T cell frequencies in MNC isolated from ileum–jejunum tissue of four protected animals measured post mortem at 21 wk
after virus challenge by ex vivo ELISpot.
(C) The group meanþ/ standard deviation profile of anti-SIV Gag p27 binding antibody titres (measured by ELISA) from animals infected with SIV ( )
and the individual profile for an SIV-infected macaque E81 (*), in which T cell ELISpot was analysed was compared with animals from which no virus was
detected following challenge (m).
doi:10.1371/journal.pmed.0050157.g003
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Blockade of SIV Rectal Infectionof virus challenge. Our working hypothesis is that this metric
provides a surrogate measure of local uptake of tenofovir;
thus only in animals where the local tissue concentration is
beyond a critical threshold is protection achieved. Using the
newly developed assay for intracellular tenofovir it should
now be possible to test this hypothesis directly. If indeed the
rate limiting step to 100% protective efﬁcacy is local uptake
of tenofovir, several possibilities require further investiga-
tion, including: is efﬁcacy increased (a) at higher concen-
trations of administered tenofovir gel; (b) with larger volumes
of administered gel; (c) with optimised gel formulations; (d)
with combinations of ARTs having differing pharmacoki-
netics; (e) with prior washing to remove residual faecal
matter? Thus, the quantiﬁcation of plasma tenofovir follow-
ing rectal administration could be used to inform the
optimisation of rectal dosing in terms of concentration,
volume, formulation, and timing to accelerate the progres-
sion of this approach to clinical trials.
Utility of the Ex Vivo Explant System
Our study has also further validated the use of the ex-vivo
rectal explant system by, for the ﬁrst time, extending its use
to macaques. Not only is this system useful for the evaluation
of antiviral compounds and combinations in vitro; as we have
shown here, it may also be used to measure antiviral activity
following application of drug in vivo. Detailed pharmacoki-
netic studies are required to determine when the peak
concentration of tenofovir appears in the plasma, but our
results from this preliminary study suggest that the peak is
early. Interestingly ileum/jejunum tissue taken from dosed
macaques remained susceptible to infection. Indeed, the lack
of drug in the small intestine was conﬁrmed by analysis of
intracellular tenofovir concentration, suggesting that secon-
dary adsorption at this site is insigniﬁcant. The relatively low
rectal dose of tenofovir applied, equating to an average of 10
lg/kg, of which a maximum of 0.19% was detected in plasma
15 min later, was far below the dose used in oral pre-exposure
prophylaxis [16]. Rectal administration of tenofovir gel may
be less likely to select for RT escape mutants even when
inadvertently used by HIV-infected individuals; however, this
possibility requires further investigations to determine the
cumulative concentration of drug entering the circulation.
Even though, following optimisation, rectal use of tenofovir
alone may prove to be sufﬁcient to confer protection, use in
combination with other topical ARVs/microbicides may be
advantageous. Experiments are in progress in vitro to model
synergistic or additive effects of drug combinations in the
explant system. Furthermore, we have recently shown that
drug combinations can protect colorectal explants against
infection with rarely transmitted RT escape mutants (C.
Herrera, unpublished data).
Possible Mechanisms of Distal Protection
At the doses used in the present study it is predicted that
the protective effects will be conﬁned to the rectal portal of
entry; however, the high degree of protection against rectal
challenge seen in the present study, including the absence of
SIV detection by highly sensitive qPCR in regional lymph
nodes was perhaps surprising given that virus may translocate
rapidly in dendritic cells [38]. An interesting possibility that
requires further investigation is that tenofovir may be
reaching local nodes through lymphatic drainage. The
interior iliac lymph nodes are known to be a site of early
virus replication and have common drainage of the female
genital tract and rectum. Indeed, targeting an SIV vaccine
preparation to the vicinity of these nodes has conferred
signiﬁcant protection from rectal challenge [39].
Although our study was not powered to allow statistical
analysis of rectal postexposure efﬁcacy, in the group of
animals receiving gel 2 h after virus exposure only one of
three animals was protected. Given that the virus replication
cycle is approximately 24 h, this preliminary observation is in
accord with the hypothesis that virus is translocated rapidly
from the portal of entry and is sequestered either in a cell in
which tenofovir is metabolised only slowly and/or that the
virus may be held in trans in a nonreplicating state, as has
been proposed for dendritic cell-mediated infection [40,41].
Thus, topical application of ARVs such as tenofovir following
local viral challenge could be used to further investigate early
virus trafﬁcking in vivo, an area of study in which there is still
a critical paucity of information.
Priming of Specific T Cells
The priming of SIV-speciﬁc T cells detectable in the
circulation in the absence of seroconversion is reminiscent of
similar responses seen in so-called highly exposed, persis-
tently seronegative individuals (reviewed in [42]). The
restriction of signiﬁcant reactivity to Gag, a structural
component of the virion, in the protected animals, suggested
the virus inoculum itself, rather than viral proteins synthes-
Table 5. Plasma Tenofovir Levels and Association with Protection from Infection
Animal
Number
Virus Status Plasma Tenofovir
Concentration (ng/ml)
Weight (kg) Estimated Total
Plasma Tenofovir (ng)
Proportion of Tenofovir
Applied Detected in
Plasma at 15 min (%)
D30 Protected 180.9 8.18 48,843 0.16
D37 Protected 130.4 10.46 44,988 0.15
D39 Protected 130 7.63 32,760 0.11
D43 Modified profile 73.3 8.02 19,424 0.06
D79 Protected 119.9 14.45 57,192 0.19
D3 Not protected 60.2 7.33 14,568 0.05
Plasma tenofovir concentration was determined 15 min after rectal administration at the time of virus challenge. Weights on the day of challenge were calculated by interpolation of
measurements taken 1 wk before and 1 wk after challenge. Total plasma tenofovir was estimated assuming a plasma volume of 33 ml/kg.
doi:10.1371/journal.pmed.0050157.t005
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Blockade of SIV Rectal Infectionised de novo, may have been processed by antigen presenting
cells either for presentation to CD4
þ T cells via MHC class II
or following processing through cross-presentation pathways,
for presentation to CD8
þ T cells via MHC class I. It is possible
that the tenofovir gel, which had not been formulated for
rectal application, resulted in transient tissue damage, as
reported for some sexual lubricants [43], resulting in seepage
of virus inoculum into the submucosa where local DC could
pick up antigen. Nonetheless, the majority of animals were
protected from infection in the current study. Alternatively a
low level of viral replication may have occurred locally with
virus spread curtailed by tenofovir-blockade of secondary
target cells. Indeed, transient early postexposure treatment of
SIV-infected macaques with tenofovir has been associated
with the stimulation of T cell responses, sometimes in the
absence of SIV-speciﬁc serum binding antibodies [44].
Interestingly, in this instance, CD8
þ lymphocytes were also
associated with resistance to rechallenge. If limited replica-
tion of virus did occur locally in the present experiment, this
may explain the apparent broadening of T cell responsiveness
in cells recovered from the intestine to include recognition of
virally encoded nonstructural antigens. The latter observa-
tion however needs cautious interpretation because of the
relatively high level of spontaneous background reactivity.
Indeed in the large intestine, spontaneous IFN-c production
was so high as to exclude analysis for antigen-speciﬁc cells,
and although considerably lower in cells recovered from the
small intestine, more work using cells recovered from SIV-
naı ¨ve macaques is required to deﬁne a robust cut-off level for
speciﬁc responses. We have reported previously that single
low dose exposure to SIV by the rectal route can induce T
and B cell priming in the absence of overt infection and a
serum antibody response [25]. It is however, far from clear
whether such responses have any antiviral signiﬁcance or
Figure 4. Colorectal Explants from Macaques Supported Replication of SIV That Was Inhibited by Pretreatment with Tenofovir In Vitro and In Vivo
(A) Replication dynamics of SIVmac251/32H in explants from two untreated animals (group F: M3, M6) in the presence or absence of exogenously added
tenofovir at 100 lg/ml. A total of 10
4 TCID50 of virus was added to each well containing three explants in a total volume of 200 ll of medium. Virus
replication was assayed by SIV Gag p27 production and mean values þ/  standard deviations are shown for four replicates of each tissue.
(B) Colorectal explants from four animals (group G: M1, M38, M5, M32) dosed in vivo with tenofovir per rectum 3 h before tissue removal were exposed
to virus in vitro (as described above) and culture supernatants assayed for Gag p27. Mean percent inhibition of SIV Gag p27 production plus standard
deviations are shown.
doi:10.1371/journal.pmed.0050157.g004
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Blockade of SIV Rectal Infectionwhether they represent a ‘‘footprint’’ of abortive virus
infection. Further detailed investigation is needed to deter-
mine if B cells are primed by virus exposure of tenofovir-
predosed animals and whether B and T cell responses can be
boosted and broadened in speciﬁcity upon subsequent
exposure to antigen. The apparent longevity of the T cell
response seen in the present study was interesting and
further work is required to analyse the dynamics of T cell
priming in this context. It is possible that the persistence of
responsiveness was due to low level boosting by sequestered
virus or antigen. Although proviral DNA was undetectable in
tissues of protected animals it is not possible to absolutely
rule out the possibility of a very low level occult infection as
has been described in macaques following intrarectal
exposure to low doses of virus (N. Polyanskaya et al.,
unpublished data) [44,45]. On-going and planned HIV-
preventative clinical trials should provide further insight
into the generation and nature of T cell responses in the
absence of overt infection. This is of importance, as
theoretically, although not supported by data on primed,
repeatedly exposed macaques (N. Polyanskaya et al., unpub-
lished data), activated CD4
þ T cells at the portal of entry
could facilitate or enhance infection by providing a pool of
target cells for virus replication. It is imperative that further
rechallenge experiments are undertaken in appropriate
macaque models before informed decisions can be made
regarding advancement of this approach to clinical trial.
Limitations of the Study
The study reported here has several limitations. Firstly, the
ARV-gel was delivered controllably under idealised condi-
tions. Ensuring that this occurs in practice will require
careful development. Secondly, ﬁnding an acceptable form of
administration may require different strategies for different
target populations. For some users application of a rectal gel
may be acceptable, for others, formulation of the ARV into a
suppository may be more acceptable. Compatibility with
other products that may be used before AI is a further
consideration. Thirdly, cell-free challenge virus was applied
in a controlled, atraumatic manner in the absence of semen.
Fourthly, the predictive value of the SIV-macaque model
requires further investigation. This issue was highlighted
recently by the much publicized failure of two large clinical
trials in HIV prevention (the Merck STEP vaccine trial, and a
trial of the vaginal microbicide cellulose sulphate), using
modalities that had apparently shown promise in the
macaque model. However, in the case of the recombinant
replication deﬁcient adenovirus vaccine (STEP trial), reduc-
tion in virus load was originally demonstrated following
immunization with a construct expressing SIV Gag and
challenge with simian HIV (SHIV)-89.6P [46]. This challenge
virus has a highly atypical biological phenotype [47], and in a
subsequent study with SIVmac239 a marginal effect was only
seen in animals expressing the Mamu-A*01 MHC class I allele
[48]. Although an enhanced effect was shown in a further
study using adenovirus constructs expressing SIV Gag, Rev,
Tat, and Nef, this approach was tested only in the more
sensitive Mamu-A*01 macaques [49]. Likewise, in the evalua-
tion of cellulose sulphate as a vaginal microbicide, the
m a c a q u ep r o t e c t i o nd a t aw e r en o td e ﬁ n i t i v ew i t ht h e
majority of treated animals showing evidence of virus
infection by PCR [50].
Conclusions
Given the caveats discussed above, our data nonetheless
suggest that rectal mucosal dosing with tenofovir shows
promise for protection against rectal transmission of an
immunodeﬁciency virus. Moreover, given the functional IFN-
c T cell responses induced, there may be potential for synergy
between topical ARV/microbicide use and vaccination as a
two-pronged strategy for preventing infection with HIV.
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Editors’ Summary
Background. About 33 million people are now infected with the human
immunodeficiency virus (HIV), which causes AIDS by killing immune
system cells. As yet, there is no cure for AIDS, although HIV infections can
be held in check with antiretroviral drugs. Also, despite years of research,
there is no vaccine available that effectively protects people against HIV
infection. So, to halt the AIDS epidemic, other ways of preventing the
spread of HIV are being sought. For example, pre-exposure treatment
(prophylaxis) with antiretroviral drugs is being investigated as a way to
prevent HIV transmission. In addition, because HIV is often spread
through heterosexual penile-to-vaginal sex with an infected partner,
several vaginal microbicides (compounds that protect against HIV when
applied inside the vagina) are being developed, some of which contain
antiretroviral drugs.
Why Was This Study Done? Because HIV can cross the membranes that
line the mouth and the rectum (the lower end of the large intestine that
connects to the anus) in addition to the membrane that lines the vagina,
HIV transmission can also occur during oral and anal sex. The lining of
the rectum in particular is extremely thin and overlies tissues rich in
activated T cells (the immune system cells that HIV targets), so
unprotected anal intercourse carries a high risk of HIV infection. Anal
intercourse is common among men who have sex with men but is also
more common in heterosexual populations than is generally thought.
Tenofovir (an antiretroviral drug that counteracts HIV after it has entered
human cells) given by mouth partly protects macaques against rectal
infection with simian immunodeficiency virus (SIV; a virus that induces
AIDS in monkeys and apes) so the researchers wanted to know whether
this drug might be effective against rectal SIV infection if applied at the
site where the virus enters the body.
What Did the Researchers Do and Find? To answer this question, the
researchers rectally infected several macaques with SIV up to 2 h after
rectal application of a gel containing tenofovir, after rectal application of
a gel not containing the drug, or after no treatment. In addition, a few
animals were treated with the tenofovir gel after the viral challenge.
Most of the animals given the tenofovir gel before the viral challenge
were partly or totally protected from SIV infection, whereas all the
untreated animals and most of those treated with the placebo gel or
with the drug-containing gel after the viral challenge became infected
with SIV. High blood levels of tenofovir 15 min after its rectal application
correlated with protection from viral infection. The researchers also
collected rectal and small intestine samples from tenofovir-treated
macaques that had not been exposed to SIV and asked which samples
were resistant to SIV infection in laboratory dishes. They found that only
the rectal samples were resistant to infection and only rectal cells
contained tenofovir. Finally, activated T cells that recognized an SIV
protein were present in the blood of some of the animals that were
protected from SIV infection by the tenofovir gel.
What Do These Findings Mean? These findings, although based on
experiments in only a few animals, suggest that rectal treatment with
antiretroviral drugs before rectal exposure to HIV might prevent rectal
HIV transmission in people. However, results from animal experiments do
not always reflect what happens in people. Indeed, clinical trials of a
potential vaginal microbicide that worked well in macaques were halted
recently because women using the microbicide had higher rates of HIV
infection than those using a control preparation. The finding that
immune-system activation can occur in the absence of overt infection in
animals treated with the tenofovir gel additionally suggests that a
combination of a local antiretroviral/microbicide and vaccination might
be a particularly effective way to prevent HIV transmission. However,
because HIV targets activated T cells, viral rechallenge experiments must
be done to check that the activated T cells induced by the virus in the
presence of tenofovir do not increase the likelihood of infection upon re-
exposure to HIV before this potential microbicide is tried in people.
Additional Information Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050157.
  Read the accompanying PLoS Medicine Perspective by Florian Hladik
  An overview of HIV infection and AIDS is available from the US
National Institute of Allergy and Infectious Diseases
  HIVInSite has comprehensive information on all aspects of HIV/AIDS,
including an article on safer sex, which includes information on the
risks associated with specific types of sex and on microbicides and
other methods to prevent the sexual transmission of HIV
  Information on all aspects of HIV/AIDS is available from Avert, an
international AIDS charity, including information on HIV prevention
and on microbicides
  The World Health Organization has a fact sheet on microbicides
  The UK charity NAM also provides detailed information on
microbicides
  PrEP Watch is a comprehensive information source on pre-exposure
prophylaxis for HIV prevention
  Global Campaign for Microbicides is an international coalition of
organisations dedicated to accelerating access to new HIV prevention
options
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